Drug intelligence / Profile preview

pimavanserin

Development stage: Approved
Lead developer: Acadia Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

Pimavanserin is an atypical antipsychotic indicated for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. Unlike most other antipsychotics, it does not block dopamine receptors but acts as a selective inverse agonist and antagonist at serotonin 5-HT2A receptor, with lower affinity for serotonin 5-HT2C receptor. This unique mechanism allows it to treat psychotic symptoms in Parkinson’s disease without worsening motor function or causing extrapyramidal side effects. Pimavanserin was first approved by the FDA in 2016 and is available as oral tablets and capsules[1][4][5][6].

Brand names: Nuplazid
Other names: pimavanserin

Targets

HTR2C (5-hydroxytryptamine 2C receptor)HTR2A (Serotonin receptor 5-HT2A)

Beyond the preview

Go deeper on pimavanserin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on pimavanserin.

Explore the full profile